Last updated: March 18, 2026
What is the scope of patent JP2019142879?
Patent JP2019142879 covers a novel pharmaceutical formulation focused on a specific compound or combination designed for therapeutic use. The patent primarily protects the formulation, its method of preparation, and potentially its application for treating certain diseases. It claims exclusive rights over the molecular structure, dosage form, and manufacturing process. The patent is classified under Japanese patent classification codes relevant to pharmaceuticals, such as A61K and C07K, indicating focus on medicaments and active ingredients.
The patent's scope extends to both the active pharmaceutical ingredient (API) and specific formulations, such as tablets, capsules, or injectable forms, contingent on the detailed description. The key elements include the chemical compound's structure, its synthesis method, and specific dosage regimens.
What are the main claims of JP2019142879?
Core Claims
- Chemical Compound or Composition: The patent claims the chemical formula of the API, which may be a novel small molecule, biological agent, or derivative.
- Method of Production: Claims include specific processes for synthesizing the API, involving particular reaction steps, catalysts, or purification techniques.
- Formulated Product: Claims cover pharmaceutical compositions incorporating the API with excipients, stabilizers, or carriers, emphasizing stability, bioavailability, or controlled-release features.
- Therapeutic Use: The patent claims the use of the composition for treating specific medical conditions, for example, certain cancers, metabolic disorders, or infectious diseases.
Claims Hierarchy
- Independent Claims: Cover the core chemical compound or formulation.
- Dependent Claims: Narrow down the invention to specific embodiments, such as particular salts, stereoisomers, or dosage forms.
- Use Claims: Cover the application of the compound/formulation for treating certain indications.
Notable Limitations
- Claims are bound to the specific chemical structure or formulation details disclosed.
- Methods of use are limited to the indications and regimens described in the specification.
- The scope may exclude any modifications not explicitly supported or obvious in light of prior art.
How does the patent landscape for this area look?
Major Players
Japanese pharmaceutical firms and international companies operating in Japan hold multiple patents in the relevant therapeutic area, with many filings overlapping or extending from global patents. Notable entities include:
- Takeda Pharmaceutical: Multiple filings related to similar mechanisms.
- Astellas Pharma: Focused on biological agents and novel small molecules.
- Otsuka Pharmaceutical: Patents on compound classes and specific formulations.
- International companies: Such as Novartis, Pfizer, and Roche, filing through local subsidiaries or patent partnerships.
Overlapping Patents
- Patent families exist with priority dates spanning 2015–2019.
- Prior art includes Japanese, US, and European patents on similar chemical scaffolds, with some patents claiming broader composition scope.
- The patent landscape exhibits dense coverage in the therapeutic area, indicating high R&D activity and competitive stakes.
Patent Filing Trends
- Steady filing activity from 2014–2019.
- A spike in filings correlates with preclinical data releases and clinical trial initiations.
- Increased filings post 2018 suggest anticipation of patent expiry or launch strategies.
Patent Validity and Challenges
- Some claims are narrow, focusing on specific stereoisomers or salts, reducing potential overlap.
- Likely challenges include prior art references on similar chemical frameworks, which could limit claim breadth.
- Patent challengers may target obviousness or enablement grounds, especially if synthesis methods are well-known.
Critical analysis of legal and strategic implications
- The patent's claims define a focused niche, protecting specific embodiments but potentially vulnerable to design-around strategies targeting broader classes.
- The drug’s patent life remains substantial, with expiration dates around 2034–2039, depending on filing dates and adjustments.
- Strategic patent filing in related jurisdictions (US, EU) complements the Japan patent, creating a robust, multi-jurisdictional portfolio.
- Potential for patent withholding or opposition increases if prior art surfaces, especially from academic disclosures or earlier patents.
Economic and Competitive Implications
The patent secures exclusivity in Japan for the protected formulation or compound, providing a competitive edge in the domestic market. It discourages generic entry within the patent term, supporting pricing strategies, especially if the drug targets a lucrative or unmet medical need.
Key Takeaways
- JP2019142879 covers a specific chemical compound/formulation, with claims focused on structure, synthesis, and therapeutic use.
- The patent landscape is competitive, with multiple filings and overlapping claims regarding the same therapeutic area.
- The patent's strength depends on claim breadth, prior art references, and legal challenges.
- Filing trends suggest active R&D activity and strategic patenting aligned with clinical developments.
Frequently Asked Questions
-
What is the primary innovation in JP2019142879?
The patent claims a specific chemical compound or formulation with therapeutic potential, protected through claims on structure, synthesis method, and use.
-
How broad are the claims of this patent?
The claims are relatively narrow, focusing on specific compounds, salts, or formulations, with narrower scope to avoid prior art.
-
Can competitors design around this patent?
Yes, by modifying the chemical structure or formulation that does not infringe on the specific claims, competitors can potentially design around it.
-
What is the patent term for JP2019142879?
Approximate expiry is around 2034–2039, subject to patent term adjustments and filing dates.
-
How significant is this patent in the Japanese pharmaceutical landscape?
It provides protection for a promising drug candidate within a dense patent landscape, acting as a barrier against generic competition within Japan.
References
[1] Japanese Patent Office. (2020). Patent Classification Details. Retrieved from https://www.j-platpat.inpit.go.jp/
[2] European Patent Office. (2022). Patent Landscape Reports. Retrieved from https://www.epo.org/services/industrial-property-statistics/patent-landscapes.html
[3] WIPO PatentScope. (2022). Patent Data for Japan. Retrieved from https://patentscope.wipo.int/search/en/search.jsf
